82 related articles for article (PubMed ID: 16322230)
1. Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice.
Chen Y; Li YH; Chen XP; Gong LM; Zhang SP; Chang ZJ; Zhang XF; Fu XY; Liu L
Cancer Res; 2005 Dec; 65(23):10838-46. PubMed ID: 16322230
[TBL] [Abstract][Full Text] [Related]
2. A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice.
Liu L; Yu XZ; Li TS; Song LX; Chen PL; Suo TL; Li YH; Wang SD; Chen Y; Ren YM; Zhang SP; Chang ZJ; Fu XY
Cancer Res; 2004 May; 64(10):3491-9. PubMed ID: 15150103
[TBL] [Abstract][Full Text] [Related]
3. The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions.
Li YH; Zhong S; Rong ZL; Ren YM; Li ZY; Zhang SP; Chang Z; Liu L
Biochem Biophys Res Commun; 2007 May; 356(2):444-9. PubMed ID: 17367757
[TBL] [Abstract][Full Text] [Related]
4. pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation.
Hirsch DS; Shen Y; Dokmanovic M; Wu WJ
Cancer Res; 2010 Jul; 70(14):5974-83. PubMed ID: 20551057
[TBL] [Abstract][Full Text] [Related]
5. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
6. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
7. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
8. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation.
Buckwalter TL; Venkateswaran A; Lavender M; La Perle KM; Cho JY; Robinson ML; Jhiang SM
Oncogene; 2002 Nov; 21(53):8166-72. PubMed ID: 12444552
[TBL] [Abstract][Full Text] [Related]
9. Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses.
Zisch AH; Pazzagli C; Freeman AL; Schneller M; Hadman M; Smith JW; Ruoslahti E; Pasquale EB
Oncogene; 2000 Jan; 19(2):177-87. PubMed ID: 10644995
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line.
Li L; Shan Y; Yang H; Zhang S; Lin M; Zhu P; Chen XY; Yi J; McNutt MA; Shao GZ; Zhou RL
Anat Rec (Hoboken); 2011 Jul; 294(7):1135-42. PubMed ID: 21618708
[TBL] [Abstract][Full Text] [Related]
11. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
12. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
13. The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity.
Laham LE; Mukhopadhyay N; Roberts TM
Oncogene; 2000 Aug; 19(35):3961-70. PubMed ID: 10962552
[TBL] [Abstract][Full Text] [Related]
14. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
15. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
16. Replacement of the conserved tyrosine 1210 by phenylalanine in the insulin receptor affects insulin-induced dephosphorylation of focal adhesion kinase but leaves other responses intact.
Van der Zon GC; Ouwens DM; Dorrestijn J; Maassen JA
Biochemistry; 1996 Aug; 35(32):10377-82. PubMed ID: 8756693
[TBL] [Abstract][Full Text] [Related]
17. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Jackson PK; Paskind M; Baltimore D
Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
[TBL] [Abstract][Full Text] [Related]
18. Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.
Jiang LQ; Feng X; Zhou W; Knyazev PG; Ullrich A; Chen Z
Oncogene; 2006 Sep; 25(40):5495-506. PubMed ID: 16636672
[TBL] [Abstract][Full Text] [Related]
19. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).
Longati P; Bardelli A; Ponzetto C; Naldini L; Comoglio PM
Oncogene; 1994 Jan; 9(1):49-57. PubMed ID: 8302603
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene.
Mitra G
Oncogene; 1991 Dec; 6(12):2237-41. PubMed ID: 1837350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
